FULCRUM THERAPEUTICS, INC. Operating Expenses
FULCRUM THERAPEUTICS, INC. (FULC) reported Operating Expenses of $29.31 million for the 3-month period ending 2026-06-30, per its S-4 filed 2026-09-02.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-09-02
- FULCRUM THERAPEUTICS, INC. operating expenses for the quarter ending 2026-06-30 was $29.31M, a 47.92% increase year-over-year.
- FULCRUM THERAPEUTICS, INC. operating expenses for the quarter ending 2026-03-31 was $22.19M, a 8.74% increase year-over-year.
- FULCRUM THERAPEUTICS, INC. operating expenses for the quarter ending 2025-12-31 was $22.69M, a 16.80% increase year-over-year.
- FULCRUM THERAPEUTICS, INC. operating expenses for the quarter ending 2025-09-30 was $21.86M, a 13.01% decline year-over-year.
- FULCRUM THERAPEUTICS, INC. operating expenses for fiscal 2023 was $113.47M, a 4.57% decline from fiscal 2022.
- FULCRUM THERAPEUTICS, INC. operating expenses for fiscal 2022 was $118.90M, a 18.65% increase from fiscal 2021.
- FULCRUM THERAPEUTICS, INC. operating expenses for fiscal 2021 was $100.22M, a 24.60% increase from fiscal 2020.
- FULCRUM THERAPEUTICS, INC. operating expenses for fiscal 2020 was $80.43M, a 4.49% decline from fiscal 2019.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $29.31M S-4 · filed 2026-09-02 | $51.50M S-4 · filed 2026-09-02 | $74.19M derived: sum of 3 quarters · filed 2026-09-02 | $96.05M derived: sum of 4 quarters · filed 2026-09-02 |
| 2026-03-31 | $22.19M 10-Q · filed 2026-04-27 | $44.88M derived: sum of 2 quarters · filed 2026-09-02 | $66.74M derived: sum of 3 quarters · filed 2026-09-02 | $86.55M derived: sum of 4 quarters · filed 2026-09-02 |
| 2025-12-31 | $22.69M derived: S-4 12 month − 10-Q 9 month · filed 2026-09-02 | $44.55M derived: sum of 2 quarters · filed 2026-09-02 | $64.37M derived: sum of 3 quarters · filed 2026-09-02 | $84.77M S-4 · filed 2026-09-02 |
| 2025-09-30 | $21.86M 10-Q · filed 2025-10-29 | $41.67M derived: sum of 2 quarters · filed 2026-09-02 | $62.08M 10-Q · filed 2025-10-29 | $81.50M derived: sum of 4 quarters · filed 2026-09-02 |
| 2025-06-30 | $19.82M S-4 · filed 2026-09-02 | $40.22M S-4 · filed 2026-09-02 | $59.65M derived: sum of 3 quarters · filed 2026-09-02 | $84.77M derived: sum of 4 quarters · filed 2026-09-02 |
| 2025-03-31 | $20.40M 10-Q · filed 2026-04-27 | $39.83M derived: sum of 2 quarters · filed 2026-09-02 | $64.96M derived: sum of 3 quarters · filed 2026-09-02 | $92.47M derived: sum of 4 quarters · filed 2026-09-02 |
| 2024-12-31 | $19.43M derived: S-4 12 month − 10-Q 9 month · filed 2026-09-02 | $44.55M derived: sum of 2 quarters · filed 2026-09-02 | $72.06M derived: sum of 3 quarters · filed 2026-09-02 | $101.90M S-4 · filed 2026-09-02 |
| 2024-09-30 | $25.13M 10-Q · filed 2025-10-29 | $52.63M derived: sum of 2 quarters · filed 2025-10-29 | $82.47M 10-Q · filed 2025-10-29 | $111.33M derived: sum of 4 quarters · filed 2025-10-29 |
| 2024-06-30 | $27.51M 10-Q · filed 2025-07-29 | $57.34M 10-Q · filed 2025-07-29 | $86.20M derived: sum of 3 quarters · filed 2025-07-29 | $114.40M derived: sum of 4 quarters · filed 2025-07-29 |
| 2024-03-31 | $29.83M 10-Q · filed 2025-05-01 | $58.70M derived: sum of 2 quarters · filed 2025-05-01 | $86.90M derived: sum of 3 quarters · filed 2025-05-01 | $115.07M derived: sum of 4 quarters · filed 2025-05-01 |
| 2023-12-31 | $28.86M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $57.06M derived: sum of 2 quarters · filed 2025-02-25 | $85.23M derived: sum of 3 quarters · filed 2025-02-25 | $113.47M 10-K · filed 2025-02-25 |
| 2023-09-30 | $28.20M 10-Q · filed 2024-11-13 | $56.37M derived: sum of 2 quarters · filed 2024-11-13 | $84.61M 10-Q · filed 2024-11-13 | $113.26M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | $28.17M 10-Q · filed 2024-07-31 | $56.41M 10-Q · filed 2024-07-31 | $85.06M derived: sum of 3 quarters · filed 2024-07-31 | $110.60M derived: sum of 4 quarters · filed 2024-07-31 |
| 2023-03-31 | $28.23M 10-Q · filed 2024-05-13 | $56.89M derived: sum of 2 quarters · filed 2024-05-13 | $82.43M derived: sum of 3 quarters · filed 2024-05-13 | $118.55M derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | $28.66M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $54.20M derived: sum of 2 quarters · filed 2024-02-27 | $90.31M derived: sum of 3 quarters · filed 2024-02-27 | $118.90M 10-K · filed 2024-02-27 |
| 2022-09-30 | $25.54M 10-Q · filed 2023-11-07 | $61.66M derived: sum of 2 quarters · filed 2023-11-07 | $90.25M 10-Q · filed 2023-11-07 | $118.86M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | $36.12M 10-Q · filed 2023-08-03 | $64.71M 10-Q · filed 2023-08-03 | $93.32M derived: sum of 3 quarters · filed 2023-08-03 | $119.03M derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | $28.59M 10-Q · filed 2023-05-15 | $57.21M derived: sum of 2 quarters · filed 2023-06-26 | $82.91M derived: sum of 3 quarters · filed 2023-06-26 | $106.97M derived: sum of 4 quarters · filed 2023-06-26 |
| 2021-12-31 | $28.62M derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-06-26 | $54.32M derived: sum of 2 quarters · filed 2023-06-26 | $78.39M derived: sum of 3 quarters · filed 2023-06-26 | $100.22M 10-K/A · filed 2023-06-26 |
| 2021-09-30 | $25.70M 10-Q · filed 2022-11-08 | $49.77M derived: sum of 2 quarters · filed 2022-11-08 | $71.60M 10-Q · filed 2022-11-08 | $93.61M derived: sum of 4 quarters · filed 2023-06-26 |
| 2021-06-30 | $24.06M 10-Q · filed 2022-08-11 | $45.90M 10-Q · filed 2022-08-11 | $67.91M derived: sum of 3 quarters · filed 2023-06-26 | $88.86M derived: sum of 4 quarters · filed 2023-06-26 |
| 2021-03-31 | $21.83M 10-Q · filed 2022-05-09 | $43.84M derived: sum of 2 quarters · filed 2023-06-26 | $64.80M derived: sum of 3 quarters · filed 2023-06-26 | $82.72M derived: sum of 4 quarters · filed 2023-06-26 |
| 2020-12-31 | $22.01M derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-06-26 | $42.96M derived: sum of 2 quarters · filed 2023-06-26 | $60.89M derived: sum of 3 quarters · filed 2023-06-26 | $80.43M 10-K/A · filed 2023-06-26 |
| 2020-09-30 | $20.95M 10-Q · filed 2021-11-04 | $38.88M derived: sum of 2 quarters · filed 2021-11-04 | $58.42M 10-Q · filed 2021-11-04 | $74.91M derived: sum of 4 quarters · filed 2023-06-23 |
| 2020-06-30 | $17.92M 10-Q · filed 2021-08-10 | $37.47M 10-Q · filed 2021-08-10 | $53.96M derived: sum of 3 quarters · filed 2023-06-23 | $70.97M derived: sum of 4 quarters · filed 2023-06-23 |
| 2020-03-31 | $19.55M 10-Q · filed 2021-05-06 | $36.04M derived: sum of 2 quarters · filed 2023-06-23 | $53.04M derived: sum of 3 quarters · filed 2023-06-23 | $66.54M derived: sum of 4 quarters · filed 2023-06-23 |
| 2019-12-31 | $16.49M derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-06-23 | $33.50M derived: sum of 2 quarters · filed 2023-06-23 | $46.99M derived: sum of 3 quarters · filed 2023-06-23 | $84.22M 10-K/A · filed 2023-06-23 |
| 2019-09-30 | $17.01M 10-Q · filed 2020-11-10 | $30.50M derived: sum of 2 quarters · filed 2020-11-10 | $67.73M 10-Q · filed 2020-11-10 | $76.98M derived: sum of 4 quarters · filed 2020-11-10 |
| 2019-06-30 | $13.49M 10-Q · filed 2020-08-11 | $50.72M 10-Q · filed 2020-08-11 | $59.97M derived: sum of 3 quarters · filed 2020-08-11 | $69.06M derived: sum of 4 quarters · filed 2020-08-11 |
| 2019-03-31 | $37.23M 10-Q · filed 2020-05-13 | $46.48M derived: sum of 2 quarters · filed 2020-05-13 | $55.57M derived: sum of 3 quarters · filed 2020-05-13 | $63.41M derived: sum of 4 quarters · filed 2020-05-13 |
| 2018-12-31 | $9.25M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-05 | $18.34M derived: sum of 2 quarters · filed 2020-03-05 | $26.19M derived: sum of 3 quarters · filed 2020-03-05 | $33.50M 10-K · filed 2020-03-05 |
| 2018-09-30 | $9.09M 10-Q · filed 2019-11-14 | $16.94M derived: sum of 2 quarters · filed 2019-11-14 | $24.25M 10-Q · filed 2019-11-14 | |
| 2018-06-30 | $7.85M 10-Q · filed 2019-08-26 | $15.16M 10-Q · filed 2019-08-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |